The most frequent grade ≥3 AEs were neutropenia (25%), ALT/AST increased (16%), diarrhea (12%), and anemia (12%).<h4>Conclusion</h4>Generally, duvelisib could offer favorable efficacy in patients with RR CLL/SLL, iNHL, MCL, and AITL. This evidence concerns the gene GPT and B-cell chronic lymphocytic leukemia.